PMID- 12827403
OWN - NLM
STAT- MEDLINE
DCOM- 20040128
LR  - 20151119
IS  - 0340-1855 (Print)
IS  - 0340-1855 (Linking)
VI  - 62
IP  - 3
DP  - 2003 Jun
TI  - [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity 
      Index (BASDAI) for use in Germany].
PG  - 264-73
AB  - OBJECTIVE: The purpose of this study was the validation of a German translation 
      of the Bath Ankylosing Spondylitis Index (BASDAI). PATIENTS AND METHODS: The 
      German translation of the BASDAI was validated using data of 134 patients with 
      ankylosing spondylitis (AS) from a spondyloarthropathy cohort. For validation the 
      BASDAI was compared with parameters assessed by physicians (physicians global, 
      C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), spinal mobility 
      (BASMI), swollen joints, enthesitis (yes or no)), and parameters assessed by 
      patients themselves (pain, function (BASFI) and quality of life (SF-12)). The 
      discriminative validity was analyzed by comparison of BASDAI scores of patients 
      subgroups who have different levels of disease severity. The sensibility to 
      change was analyzed by using follow-up data of a clinical trial on efficacy of 
      the anti-tumor necrosis factor (TNF) alpha agent infliximab in 70 AS-patients 
      with active and severe disease. RESULTS: The German translation of the BASDAI was 
      easy to understand, the translation back to English corresponded well with the 
      original English version. The 6 questions of the BASDAI represent different 
      aspects of disease but correlated also well with each other (r < 0.65). There was 
      a good internal consistency for all 6 questions (Cronbach's Alpha 0.82), strong 
      correlations to the physician's global (r = 0.659), pain (r = 789), function 
      (BASFI; r = 0.752) and to CRP and ESR confirming that the BASDAI assesses a 
      comprehensive picture of patient's disease activity. For subgroups of patients 
      with different levels of disease severity or with different manifestations the 
      BASDAI showed good discriminative properties. The BASDAI was sensitive to change 
      during treatment with infliximab (effect size 1.18). CONCLUSION: The German 
      translation of the BASDAI is easy to use, reliable, and sensitive to change for 
      the assessment of disease activity in AS.
FAU - Brandt, J
AU  - Brandt J
AD  - Klinikum Benjamin Franklin, Medizinische Klinik I, Rheumatologie, Hindenburgdamm 
      30, 12200 Berlin, Germany. jan.brandt@medizin.fu-berlin.de
FAU - Westhoff, G
AU  - Westhoff G
FAU - Rudwaleit, M
AU  - Rudwaleit M
FAU - Listing, J
AU  - Listing J
FAU - Zink, A
AU  - Zink A
FAU - Braun, J
AU  - Braun J
FAU - Sieper, J
AU  - Sieper J
LA  - ger
PT  - Clinical Trial
PT  - Comparative Study
PT  - English Abstract
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
TT  - Validierung einer deutschen Version des Fragebogens BASDAI zur Messung der 
      Krankheitsaktivitat bei ankylosierender Spondylitis.
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - B72HH48FLU (Infliximab)
SB  - IM
MH  - Activities of Daily Living/*classification
MH  - Adult
MH  - Antibodies, Monoclonal/adverse effects/therapeutic use
MH  - Antirheumatic Agents/adverse effects/therapeutic use
MH  - Cohort Studies
MH  - Cross-Cultural Comparison
MH  - Disability Evaluation
MH  - Female
MH  - Follow-Up Studies
MH  - Germany
MH  - Humans
MH  - Infliximab
MH  - Language
MH  - Male
MH  - Middle Aged
MH  - Pain Measurement/*statistics & numerical data
MH  - Psychometrics/statistics & numerical data
MH  - Reproducibility of Results
MH  - Spondylarthropathies/classification/*diagnosis
MH  - Spondylitis, Ankylosing/classification/*diagnosis/drug therapy
MH  - Treatment Outcome
MH  - Tumor Necrosis Factor-alpha/antagonists & inhibitors
EDAT- 2003/06/27 05:00
MHDA- 2004/01/30 05:00
CRDT- 2003/06/27 05:00
PHST- 2003/06/27 05:00 [pubmed]
PHST- 2004/01/30 05:00 [medline]
PHST- 2003/06/27 05:00 [entrez]
AID - 10.1007/s00393-003-0522-y [doi]
PST - ppublish
SO  - Z Rheumatol. 2003 Jun;62(3):264-73. doi: 10.1007/s00393-003-0522-y.